Records containing: Non Hodgkin Lymphoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-06-27Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
-
CLINICAL_TRIALS study record update · 2025-06-12Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
-
CLINICAL_TRIALS study record update · 2025-06-04An Early Clinical Study to Evaluate the Safety and Clinical Efficacy of STR-P004 in Subjects With Relapsed/Refractory CD19-Positive B-Lymphocytic Non-Hodgkin's Lymphoma
-
CLINICAL_TRIALS study record update · 2025-05-29A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
-
CLINICAL_TRIALS study record update · 2025-05-15Phase I Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-05-13Liposomal Mitoxantrone Hydrochloride, Gemcitabine, Vinorelbine With or Without Rituximab (GVM±R) in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
-
CLINICAL_TRIALS study record update · 2025-05-04A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
-
CLINICAL_TRIALS study record update · 2025-05-02Pilot Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
-
CLINICAL_TRIALS study record update · 2025-04-22A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.
-
CLINICAL_TRIALS study record update · 2025-04-16A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Properties of Orally Administered APG-2575 in Patients With Hematologic Malignancies
-
CLINICAL_TRIALS study record update · 2025-04-10An Open-Label, Non-Randomized Clinical Study to Evaluate Pharmacokinetic (PK) Profiles, Safety, and Tolerability of Abexinostat Monotherapy in Patients With Non-Hodgkin's Lymphoma Who Have Failed Standard of Care
-
CLINICAL_TRIALS study record update · 2025-03-28An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) As a Single Agent and in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
-
CLINICAL_TRIALS study record update · 2025-03-24A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
-
CLINICAL_TRIALS study record update · 2025-02-24NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
-
CLINICAL_TRIALS study record update · 2025-02-18A Phase 1, Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) in Japan
-
CLINICAL_TRIALS study record update · 2025-02-11Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study
-
CLINICAL_TRIALS study record update · 2025-02-04A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
-
CLINICAL_TRIALS study record update · 2025-02-03A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
-
CLINICAL_TRIALS study record update · 2024-12-19ADMINISTRATION of LMP-SPECIFIC CYTOTOXIC T-LYMPHOCYTES to PATIENTS with RELAPSED EBV-POSITIVE LYMPHOMA
-
CLINICAL_TRIALS study record update · 2024-12-18The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
-
CLINICAL_TRIALS study record update · 2024-12-10A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
-
CLINICAL_TRIALS study record update · 2024-11-20A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored Clinical Study
-
CLINICAL_TRIALS study record update · 2024-11-15Phase 1 and Dose Expansion Study of APR-246 in Combination With Acalabrutinib or Venetoclax-based Therapy in Subjects With R/R NHL Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
-
CLINICAL_TRIALS study record update · 2024-11-13A Phase I/II Study Evaluating ZX-101A in Patients with Relapsed/Refractory Hematological Malignancies
-
CLINICAL_TRIALS study record update · 2024-10-24Bendamustine + Obinutuzumab Induction Chemoimmunotherapy With Risk-adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma